The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

IL-23 and Th17 cells are key players in tissue immunosurveillance and are implicated in human immune-mediated diseases. Genome-wide association studies have shown that the IL23R R381Q gene variant protects against psoriasis, Crohn's disease and ankylosing spondylitis. We investigated the immunological consequences of the protective IL23R R381Q gene variant in healthy donors. The IL23R R381Q gene variant had no major effect on Th17 cell differentiation as the frequency of circulating Th17 cells was similar in carriers of the IL23R protective (A) and common (G) allele. Accordingly, Th17 cells generated from A and G donors produced similar amounts of Th17 cytokines. However, IL-23-mediated Th17 cell effector function was impaired, as Th17 cells from A allele carriers had significantly reduced IL-23-induced IL-17A production and STAT3 phosphorylation compared to G allele carriers. Our functional analysis of a human disease-associated gene variant demonstrates that IL23R R381Q exerts its protective effects through selective attenuation of IL-23-induced Th17 cell effector function without interfering with Th17 differentiation, and highlights its importance in the protection against IL-23-induced tissue pathologies.

[1]  T. Mcclanahan,et al.  Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis , 2010, The Journal of Immunology.

[2]  F. Powrie,et al.  Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells , 2010, Immunity.

[3]  T. Mcclanahan,et al.  Human Th17 Cells Comprise Heterogeneous Subsets Including IFN-γ–Producing Cells with Distinct Properties from the Th1 Lineage , 2010, The Journal of Immunology.

[4]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[5]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[6]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[7]  K. Duffin,et al.  Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. , 2009, The Journal of investigative dermatology.

[8]  Judy H. Cho,et al.  IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. , 2009, Annual review of medicine.

[9]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[10]  Erin E. Murphy,et al.  Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation , 2009, The Journal of experimental medicine.

[11]  Zhiming Lin,et al.  Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis , 2009, Rheumatology International.

[12]  T. Mcclanahan,et al.  The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.

[13]  F. Powrie,et al.  The interleukin‐23 axis in intestinal inflammation , 2008, Immunological reviews.

[14]  E. van de Vosse,et al.  IL-23 and IL-12 responses in activated human T cells retrovirally transduced with IL-23 receptor variants. , 2008, Molecular immunology.

[15]  A. Fischer,et al.  Mutations in STAT3 and IL12RB1 impair the development of human IL-17–producing T cells , 2008, The Journal of experimental medicine.

[16]  V. Kuchroo,et al.  Induction and effector functions of TH17 cells , 2008, Nature.

[17]  E. Barillot,et al.  A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses , 2008, Nature Immunology.

[18]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[19]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[20]  S. Brand,et al.  Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL‐22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status , 2008, Inflammatory bowel diseases.

[21]  M. González-Gay,et al.  The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[22]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[23]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[24]  Frank O. Nestle,et al.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis , 2007, Human Genetics.

[25]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[26]  Steven J. Schrodi,et al.  A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.

[27]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[28]  F. Powrie,et al.  Interleukin-23 drives innate and T cell–mediated intestinal inflammation , 2006, The Journal of experimental medicine.

[29]  L. Presta,et al.  Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. , 2006, The Journal of clinical investigation.

[30]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[31]  T. Giese,et al.  Expression of Interleukin‐12‐Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin‐23p19 and Interleukin‐27p28 in Crohn's Disease But Not in Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[32]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[33]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[34]  T. Mcclanahan,et al.  Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation , 2003, The Journal of experimental medicine.

[35]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[36]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[37]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[38]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[39]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[40]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.